<DOC>
	<DOCNO>NCT02389881</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics multiple dos TAK-058 healthy non-elderly elderly participant .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Multiple-Dose TAK-058 Healthy Participants</brief_title>
	<detailed_description>The drug test study TAK-058 , evaluation treatment schizophrenia . This study enroll approximately 32 healthy non-elderly 8 healthy elderly participant . Participants randomly assign ( chance , like flip coin ) one five treatment groupsâ€”which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Cohort 1 Non-elderly Healthy : TAK-058 25 mg - Cohort 2 Non-elderly Healthy : TAK-058 75 mg - Cohort 3 Non-elderly Healthy : TAK-058 150 mg - Cohort 4 Elderly Healthy : TAK-058 25 mg - Cohort 5 Non-elderly Healthy : TAK-058 300 mg - Cohort 1-4 Non Elderly Placebo ( dummy inactive solution ) - oral solution look like study drug active ingredient . - Cohort 5 Elderly Placebo This single-center trial conduct United States . The overall time participate study 40 day assign Cohort 1 4 . Participants confine clinic 12 day , contact telephone 11 30 day last dose study drug follow-up assessment ( Days 21 40 ) . The overall time participate study 14 day assign Cohort 5 . Participants confine clinic 4 day , contact telephone 14 day last dose study drug follow-up assessment ( Day 14 ) .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Ages study 18 60 year nonelderly 18 65 year elderly . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose . A female participant childbearing potential , defined subject surgically sterilize ( hysterectomy , bilateral oophorectomy tubal ligation ) postmenopausal ( define continuous amenorrhea least 2 year folliclestimulating hormone [ FSH ] &gt; 40 IU/L ) . Weighs least 45 kg ( 99 lb ) body mass index ( BMI ) 18.0 30.0 kg/m^2 , inclusive Screening . Has receive investigational compound within 30 day prior first dose study medication . Has receive TAK058 previous clinical study . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . Has know hypersensitivity component formulation TAK058 . Has positive urine drug result drug abuse Screening Checkin ( Day 1 ) . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 6 month prior Screening Visit unwilling agree abstain alcohol drug throughout study . Female participant childbearing potential ( premenopausal , nonsterilized ) , positive pregnancy test . Male participant intend donate sperm course study 12 week thereafter . Has evidence current cardiovascular , central nervous system , hepatic , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma hypoxemia , hypertension , seizure , allergic skin rash . There find subject 's medical history , physical examination , safety laboratory test give reasonable suspicion disease would contraindicate take TAK058 , similar drug class , might interfere conduct study . This include , limited , peptic ulcer disease , seizure disorder cardiac arrhythmia . Has previously seizure convulsion ( lifetime ) , include absence seizure febrile convulsion . Has current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( ie , history malabsorption , surgical intervention know impact absorption [ eg , bariatric surgery bowel resection ] , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn ) . Has history cancer malignancy , except basal cell carcinoma remission least 5 year prior Day 1 . Has positive test result hepatitis B surface antigen ( HBsAg ) , antibody hepatitis C virus ( antiHCV ) know history human immunodeficiency virus infection Screening . Has poor peripheral venous access . Has donate lose 450 mL blood volume ( include plasmapheresis ) , transfusion blood product within 45 day prior Day 1 . Has Screening Checkin ( Day 1 ) abnormal ( clinically significant [ CS ] ) electrocardiogram ( ECG ) . Has supine blood pressure outside range 90 140 mm Hg systolic 60 90 mm Hg diastolic , confirm one repeat test within maximum 5 minute , Screening Visit Checkin ( Day 1 ) Visit . Has rest heart rate outside range 50 100 bpm , confirm repeat test within maximum 5 minute , Screening Visit Checkin ( Day 1 ) Visit . Has QT interval Fridericia 's correction method ( QTcF ) &gt; 450 m ( male ) &gt; 470 m ( female ) PR outside range 120 220 m , confirm one repeat test within maximum 5 minute , Screening Visit Checkin ( Day 1 ) Visit . Has abnormal Screening Checkin ( Day 1 ) laboratory value suggest CS underlying disease subject follow lab abnormality : ALT and/or AST &gt; 1.5 upper limit normal . Has risk suicide accord investigator 's clinical judgment ( eg , per ColumbiaSuicide Severity Rating Scale [ CSSRS ] ) make suicide attempt previous 6 month . Has uncontrolled , CS neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , immunologic , endocrine disease , psychiatric disorder , abnormality , may impact ability subject participate potentially confound study result . Has use nicotinecontaining product ( include limit cigarette , electronic cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin ( Day 1 ) . Cotinine test positive Screening Checkin ( Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>